Medical Management of Persistent and Recurrent Cushing Disease

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations


Recent evidence supports the notion that the incidence of Cushing disease is higher than previously thought. Transphenoidal surgery, in the hands of experienced neurosurgeons, is currently considered the first-line treatment of choice. However, an examination of remission and recurrence rates in long-term follow-up studies reveals that potentially up to 40% to 50% of patients could require additional treatment. If left untreated, the resultant morbidity and mortality are high. Successful clinical management of patients with Cushing disease remains a challenge. The development of new therapeutic agents has been eagerly anticipated. This article discusses the results of currently available and promising new therapeutic agents used to treat this challenging disease.

Original languageEnglish (US)
Pages (from-to)653-668
Number of pages16
JournalNeurosurgery clinics of North America
Issue number4
StatePublished - Oct 2012


  • Adrenal steroidogenesis inhibitors
  • Cushing disease
  • Failed transphenoidal surgery
  • Glucocorticoid receptor antagonist
  • Mifepristone
  • Pasireotide
  • Recurrent Cushing disease
  • Somatostatin receptor ligands

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology


Dive into the research topics of 'Medical Management of Persistent and Recurrent Cushing Disease'. Together they form a unique fingerprint.

Cite this